WHO advises against Regeneron and GSK Covid-19 treatments

The World Health Organization ”strongly” recommends that the two antibodies no longer be used, some months after the FDA limited the use of one medicine and scrapped the other. (Corrected)

Photo: Hannah Beier/Reuters/Ritzau Scanpix

(Corrected Sept. 20: An earlier version of this article mistakenly stated that one of the drugs was made by Pfizer/Regeneron when it was actually Roche/Regeneron. MedWatch apologizes for the mistake).

The World Health Organization (WHO) can no longer support the use of two Covid-19 antibody treatments, sotrovimab and casirivimab-imdevimab, developed by GSK/Vire Biotechnology and Regeneron/Roche, respectively, Reuters reports.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs